Close Menu

And It Did Work

The New York Times has a Q&A with Brian Druker, the researcher who developed Gleevec. When Druker started out as an oncologist in the '80s, "cancer was seen as something like a light switch that was stuck in an 'on' position. You were given a baseball bat, which was chemotherapy, and told to knock the light out with the bat," he says. That led him to study how cell growth is regulated and, eventually, brought him to Gleevec, which is now used by about 200,000 people.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.